BenchSci is a technology company.
BenchSci has raised $157.2M across 8 funding rounds.
Key people at BenchSci.
BenchSci has raised $157.2M in total across 8 funding rounds.
BenchSci has raised $157.2M in total across 8 funding rounds.
BenchSci's investors include Afore Capital, BDC Venture Capital, Blank Ventures, Felicis Ventures, F-Prime Capital Partners, Golden Ventures, Gradient Ventures, Graph Ventures, Ground Up Ventures, GSV Acceleration, Indicator Ventures, iNovia Capital.
Key people at BenchSci.
BenchSci is a Toronto-based technology company that builds AI-powered software for preclinical R&D in biopharma, primarily through its ASCEND platform.[1][2][3][4] ASCEND uses machine learning and a proprietary Biological Evidence Knowledge Graph (BEKG) trained on over 20 million scientific publications, multi-omics data, and client proprietary data to map disease biology, aiding target identification, experiment design, and risk assessment.[1][3][4] It serves pharmaceutical companies (16 of the top 20), biotech firms, and over 4,500 academic institutions, solving key pain points like unreliable reagents, inefficient antibody selection, and biology misinterpretation that delay drug discovery.[3][4][6] With over $200 million raised and 350+ employees, BenchSci demonstrates strong growth, including Deloitte Tech Fast 50 recognition and adoption by 50,000+ scientists.[3][5][7]
BenchSci was founded in 2015 by four co-founders, including CEO Liran Belenzon, emerging from the Creative Destruction Lab (CDL) accelerator in Toronto.[3][5] The idea stemmed from frustrations in biomedical research, particularly the inefficiency of selecting reliable antibodies from millions of options amid unreliable results in publications, wasting time and resources.[6] Early focus was on an AI-powered search engine for biological reagents like antibodies, enabling 24x faster and 75% cheaper selection by decoding scientific papers.[6] Pivotal moments include a Series A raise in 2018 from Gradient Ventures (Google's AI fund)—the first for a non-US medtech firm—and the 2023 launch of ASCEND, expanding to a full generative AI platform for disease biology.[3][6] This evolution propelled growth from a small team to enterprise scale, securing investors like F-Prime Capital (2020 investment), TCV, and iNovia.[1][3][5]
BenchSci rides the AI-for-drug-discovery wave, leveraging generative AI and knowledge graphs amid exploding biomedical data volumes, where traditional methods fail due to complexity and noise.[3][4][5] Timing aligns with post-2023 AI maturity (e.g., LLMs), regulatory pushes for faster R&D, and biopharma's $2T+ annual spend, where 90% of failures trace to biology errors.[7] Market tailwinds include multi-omics integration and publisher data access, positioning BenchSci to cut timelines via "evidence-first" AI, influencing ecosystems by standardizing traceable research and enabling smaller biotechs via academic tools.[1][3][6] It democratizes elite insights, accelerating therapies in oncology, immunology, and beyond while competing in a fragmented field (e.g., vs. L7 Informatics, Collaborative Drug Discovery).[2]
BenchSci is primed to dominate enterprise AI for biopharma R&D, expanding ASCEND with deeper multimodal capabilities and real-time clinical integrations to further slash discovery failures.[4][8] Trends like agentic AI, federated learning for proprietary data, and personalized medicine will amplify its edge, potentially doubling adoption as pharma mandates AI workflows.[3][5] Influence may evolve toward platform-orchestrating entire pipelines, fostering an ecosystem of AI-ready tools and partnerships, ultimately delivering medicines faster and cementing its role as the "scientist's co-pilot" in decoding disease biology.[1][7] This builds on its mission to exponentially boost life-saving R&D speed and quality.[3][7]
BenchSci has raised $157.2M across 8 funding rounds. Most recently, it raised $70.0M Series D in May 2023.
